The Short-Sellers May Be Right About This Red-Hot Pharma Stock

Company Overview - Palvella Therapeutics (PVLA) is a clinical-stage biopharmaceutical company valued at $1.11 billion, focusing on novel therapies for rare genetic skin diseases [2]. - The company currently has no revenue or FDA pipeline, making it highly speculative and suitable for traders rather than long-term investors [5]. Stock Performance - PVLA has demonstrated exceptional price momentum, with shares up 508% over the past year and gaining 295.85% since a "Buy" signal was issued on July 9 [3][5]. - The stock recently reached a new 2-year high of $103 during trading on November 24 [4]. - PVLA has made 11 new highs and gained 39.9% in the last month, indicating strong recent performance [6]. Technical Indicators - The stock has a Weighted Alpha of +559.87 and a Relative Strength Index (RSI) of 73.22, suggesting strong upward momentum [6]. - Barchart has a 100% "Buy" opinion on PVLA, and the Trend Seeker "Buy" signal remains intact [6]. - The current trading price is $102.76, with a 50-day moving average of $72.97, and a technical support level around $90.92 [6].